Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 2 of 5 for:    Gemini | Macular Degeneration

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04643886
Recruitment Status : Terminated (no further benefit)
First Posted : November 25, 2020
Last Update Posted : April 4, 2022
Information provided by (Responsible Party):
Gemini Therapeutics, Inc.

Brief Summary:
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Condition or disease Intervention/treatment Phase
Dry Age-related Macular Degeneration Geographic Atrophy Macular Degeneration Retinal Disease Retinal Degeneration Drug: GEM103 Phase 2

Detailed Description:

This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Actual Study Start Date : July 30, 2020
Actual Primary Completion Date : February 18, 2022
Actual Study Completion Date : March 21, 2022

Arm Intervention/treatment
Experimental: Cohort with Genetic Profile A

Subjects will have Genetic Profile A.

Intervention: Biological: GEM103.

Drug: GEM103

Experimental: Cohort with Genetic Profile B

Subjects will have Genetic Profile B.

Intervention: Biological: GEM103

Drug: GEM103

Primary Outcome Measures :
  1. Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events. [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale. [ Time Frame: 6 months ]
  2. To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible. [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. At least 50 years old at the time of signed informed consent.
  2. Must have one of the following genetic profiles:

    1. Genetic Profile A.
    2. Genetic Profile B.
  3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).
  4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.
  5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.
  6. Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.

Exclusion Criteria:

  1. Presence of the following ocular conditions - in the study eye:

    1. Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.
    2. Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.
    3. Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.
    4. Aphakia or complete absence of the posterior capsule.
    5. History of laser therapy to the macula or fundus or extensive laser to the retina.
    6. Prior corneal transplant.
  2. Presence of any of the following ocular conditions - in either eye:

    1. History of herpetic infection.
    2. Concurrent disease that could require medical or surgical intervention during the study period.
    3. Active uveitis and/or vitritis (grade: trace or above).
    4. History of idiopathic or autoimmune-associated uveitis.
    5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.
    6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.
  3. In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.
  4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.
  5. Current use of medications known to be toxic to the lens, retina, or optic nerve.
  6. Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04643886

Show Show 29 study locations
Sponsors and Collaborators
Gemini Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Gemini Therapeutics, Inc. Identifier: NCT04643886    
Other Study ID Numbers: GEM-CL-10302
REGATTA ( Other Identifier: Gemini Therapeutics )
First Posted: November 25, 2020    Key Record Dates
Last Update Posted: April 4, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Retinal Diseases
Retinal Degeneration
Eye Diseases
Pathological Conditions, Anatomical
Eye Diseases, Hereditary